nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01752257,EF5 in Melanoma Patients,0.002203737326304247,0.0010009464353049394
NCT01760499,"Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study",0.000723492071442262,0.0009650884236020795
NCT01748747,Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery,0.0010468862630533835,0.001319853488903554
NCT01748448,Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome,0.001024525291797672,0.0007270584728593636
NCT01703507,Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma,0.0008959145285707683,0.0009591979656584367
NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,0.0022037373263042444,0.0024132581368549355
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",0.0009630198664935007,0.0007626970333981655
NCT01727076,"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer",0.0010554399226649822,0.0012328001819836222
NCT01723813,Peptide Vaccinations Plus GM-CT-01 in Melanoma,0.0010598452343715695,0.0011198945887920019
NCT01744171,Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma,0.001291642507780212,0.0014599935554798177
NCT01744860,Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples,0.0007707354551312124,0.0009557523176075541
NCT01767454,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,0.0009514611240248654,0.0009645200473196249
NCT01704287,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002),0.0010230664443799308,0.0008828622905104079
NCT01776905,In Vivo Real-time Detection of Circulating Melanoma Cells,0.0010569694484415147,0.0007523835801333082
NCT01740401,CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma,0.0010915421799021702,0.0010745611400146606
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,0.0011242441789030028,0.0010046376029229731
NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients",0.0011565836444614693,0.0011385276138957707
NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,0.0011316325209985675,0.0012989225400409185
NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,0.0009143436362416354,0.0009809692559167495
NCT01789827,Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy,0.0011537415220205362,0.001172243205285797
NCT01721746,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),0.0012157244727844854,0.0012100053371317426
NCT01721603,A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,0.0008691773258599376,0.0009144276401277451
NCT01708941,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.001126432520489862,0.001224188726553327
NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,0.0014907480331165155,0.0008995524447447028
NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,0.0010483488961406098,0.0010484863785016356
NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,0.0009235324953642374,0.0010421457835344205
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.0008552651897102873,0.0008776980357999971
NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,0.0008824134774543904,0.0009953449512126534
NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,0.0011267003273012144,0.0009263407823805415
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,0.0014315594858057893,0.001164927047810205
NCT01709162,Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma,0.0009818400699185238,0.0011878178579718054
NCT01782508,A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma,0.0008987023934116465,0.0008932565423243228
NCT02836548,HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma,0.0008441516681684817,0.001052455947540052
NCT02891616,18F-FLT PET Imaging in Patients With Advanced Melanoma,0.0011764488539874243,0.001173038938836771
NCT02879474,Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma,0.0010180341844270974,0.0008374482937813489
NCT02819843,"A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",0.000875687461999198,0.0009018197296521492
NCT02884362,Prospective Melanoma Database,0.001450674460813994,0.0005277048761414362
NCT02883933,Clinical and Histological Features of Head and Neck Melanoma,0.0010373651045929913,0.0005803158793805319
NCT02828202,Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients,0.0012968884073686208,0.0014510129567468133
NCT02828345,Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma,0.0012296366789055712,0.0012104176508096335
NCT02874040,Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser),0.000736798521502083,0.0009367814722460218
NCT02858869,Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,0.0007775075076066624,0.000966240471920937
NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",0.0008272998469919191,0.0010316921416571618
NCT02854124,Tracing Dissemination of Melanoma Cells in Healthy Tissues,0.0010637599677526652,0.0008842090119450316
NCT02854657,Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners,0.001068430155001964,0.0009405769130808563
NCT02897765,"A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",0.0010098432769041525,0.0011670900976528426
NCT02818023,Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,0.0010332402274170383,0.0013110430513889248
NCT02838433,Study of Anti-telomerase T CD4 Immunity in Melanoma,0.0012556199754063435,0.0010233578334416184
NCT02870244,Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes,0.0008840818700881455,0.0007601964050016164
NCT02862145,"Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions",0.0011333629191995634,0.0009721462843722941
NCT02862743,Molecular Characterization of Advanced Stage Melanoma by Blood Sampling,0.0008212861066777463,0.0008399251972630164
NCT02823405,X4P-001 and Pembrolizumab in Patients With Advanced Melanoma,0.0013634693013109764,0.0010984131840402797
NCT02857374,Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy,0.0010046923618367814,0.0010953845511568413
NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,0.001528376627783672,0.0012825696246519692
NCT01588847,Anesthesia and Cancer Recurrence im Malignant Melanoma,0.0008484419770811494,0.0007554248298775752
NCT01557114,Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma,0.0014154389374292657,0.0014392942232314843
NCT01528774,Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers,0.0007571462051330479,0.0008826448319844298
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,0.0012150489999564172,0.001071357808891366
NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,0.001120735819751223,0.0013411071666458959
NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients,0.0012242721272729324,0.0010676353742212939
NCT01551693,STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma,0.0012968884073686208,0.0010308178427366488
NCT01522664,A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma,0.0012895079976448798,0.0010177929988139979
NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",0.0009148676087216652,0.00099049931495568
NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,0.0008650455849982803,0.0011669167766551317
NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,0.0010766178612876022,0.001048783955685147
NCT01502293,Trial of pIL-12 Electroporation Malignant Melanoma,0.0010304124789648685,0.0010420777227091887
NCT01502696,Adjuvant PEG Intron in Ulcerated Melanoma,0.001023531366101294,0.0010539899838942482
NCT01558349,Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques,0.0014536501664927262,0.0010913420325945444
NCT01546571,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",0.0012385301293054642,0.0015136889091057182
NCT01531608,Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma,0.0008534484447662512,0.0008640547880604745
NCT01531244,"Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma",0.0008175407557190591,0.0011563966707966071
NCT01565837,Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,0.0008440230103133635,0.0010621931786950188
NCT01500304,Minimally Invasive Groin Dissection for Melanoma,0.000830536610451012,0.0008928034243938684
NCT01563614,"A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain",0.00100847069784796,0.0008270313663171705
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,0.001239661344498301,0.001091417307446648
NCT01533948,Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery,0.0010869406551367686,0.0013924550332386164
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,0.0009187865641213892,0.0009454710791491513
NCT01556503,Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis,0.0008450146056864721,0.0008722771750443947
NCT01503827,Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma,0.0007723145510488315,0.0007235289743328039
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,0.0012171969458726836,0.0007940815290946223
NCT01543113,"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project",0.0007812431157877804,0.001081276748376086
NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,0.0011250507169134805,0.001357869693830578
NCT02203864,Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma,0.0011786621062737505,0.001211812978095072
NCT02223884,A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy,0.0009026701994155335,0.0009689614757241261
NCT02257424,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",0.0010594919206541663,0.0011563240522224519
NCT02251314,Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma,0.0010697659376858602,0.0008424015200408059
NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL,0.0012153558438749161,0.0014399201812499403
NCT02225366,Intratumoral Injections of LL37 for Melanoma,0.0014608344511098706,0.0010938475627956313
NCT02275416,Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma,0.0011012344435120827,0.0011439290372127098
NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,0.0012153126339152517,0.0009950339913248306
NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,0.0008698083019677817,0.000983687571062221
NCT02211131,Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma,0.0009032484870195802,0.0010543273710736777
NCT02297529,Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma,0.0009804860888361479,0.0011492203103675596
NCT02236546,FDG-PET in Advanced Melanoma,0.001190834366060206,0.0010654438949948323
NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,0.00135711220636099,0.0012970679834835885
NCT02263508,Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034),0.0008726649311249687,0.0008126609458155628
NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,0.0015793609572423341,0.0011383736696780912
NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,0.0008716608578738206,0.0011155098326456425
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,0.0011103725360014488,0.0012513227167678155
NCT02231775,Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo),0.001050353936265003,0.001101504270729109
NCT00590824,Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma,0.0010688521356377982,0.0008239245656625057
NCT00591500,A Model for Genetic Susceptibility: Melanoma,0.0008320912635367526,0.0007272793296394942
NCT00591370,Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma,0.0012360013082588185,0.0010806181885362916
NCT00518206,Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma,0.001301148608649393,0.0011690288889879047
NCT00518895,Trial of Dacarbazine With or Without Genasense in Advanced Melanoma,0.0009729063955312053,0.0009127805809331362
NCT00580320,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,0.0009036477249665813,0.0009249199307304151
NCT00580060,"Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",0.0009885144798283643,0.0011343577357732404
NCT00539591,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,0.0009664549544759393,0.0011284941158332484
NCT00577382,SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,0.0012637062868022027,0.0009584029979100587
NCT00510302,Melanoma Risk-Reduction Among Patients and Family Members,0.0012148293197187536,0.0007049619726710244
NCT00584493,Treatment Use Study for Advanced Melanoma.,0.0011971873192124596,0.0014661956721059549
NCT00581698,Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue,0.0006971772538804888,0.0008404064168738292
NCT00526032,Melanoma Detection by Oblique-Incidence Optical Spectroscopy,0.001028511477323457,0.0005997224221576443
NCT00565968,Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg,0.001027550887488772,0.0010146656319736126
NCT00596362,Treatment With Intravitreal Avastin for Large Uveal Melanomas,0.0011101791776048913,0.0011046163790167797
NCT00533702,A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma,0.0010734757130318698,0.0010655362070243085
NCT00553618,"Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients",0.0010137594175074725,0.0011292565892907572
NCT00553306,Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma,0.001068841824205001,0.0011343790435667694
NCT00559026,Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients,0.0011694880992827027,0.0010360100583671284
NCT00525031,Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients,0.0010173806255808222,0.0013806399704056043
NCT00522834,Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma,0.000847821502040004,0.0007641694183476487
NCT00521001,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,0.0011138303221349354,0.0011017089003387147
NCT00585000,"A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",0.00121962345654217,0.0013002690385753547
NCT00515983,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,0.0010912950287901423,0.0012145220791872722
NCT00588198,"Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma",0.0009676387177036208,0.0012378922561829524
NCT00588341,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,0.0010632435702688015,0.0011963316214498435
NCT00535314,Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma,0.001221407319680041,0.0012974514797256787
NCT00506311,Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients,0.0012236832711386182,0.0006918575961793448
NCT00543205,"Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment",0.0007597434072524925,0.0006813035763168155
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,0.0010287966448641686,0.0010022063206423452
NCT00568451,Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma,0.0011066084194117447,0.0010959094073476657
NCT00568048,Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011191126475989931,0.0010838396784978391
NCT00507325,Sample Collection From Melanoma Patients,0.0015274128238253535,0.0011968497646153806
NCT00536029,MicroRNA Expression and Function in Cutaneous Malignant Melanoma,0.0010276521035079685,0.0006707210811098225
NCT00512798,Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma,0.0011262816328048964,0.001049986217105213
NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,0.0014521271580457957,0.0009086799876571401
NCT00527761,Taxotere/Temodar/Cisplatin Study in Melanoma Patients,0.0011265461436110375,0.0011032789889758663
NCT00527657,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.0010820641915710652,0.0010505356870268241
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,0.0012096662509283214,0.000889179438644669
NCT00538005,"Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",0.0010342110330453262,0.0010314497433856625
NCT02739386,Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases,0.0011555765604807527,0.0009760174203951171
NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,0.0011191625075674984,0.001103599117777942
NCT02791594,Imaging FDG Flare in Melanoma,0.0010339564178663172,0.0010016551140905603
NCT02723721,Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face,0.0008321510612443962,0.0008365085393799072
NCT02723006,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",0.0009265660478553929,0.0010462811141106994
NCT02717364,"Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma",0.0011019822703250077,0.000945093132075633
NCT02799901,Nivolumab Plus Radiotherapy in Advanced Melanoma,0.0009948460088925726,0.0008245276751746802
NCT02794636,Interferon Toxicities in Melanoma Treatment,0.0009045035436485323,0.0010497628365440412
NCT02716948,SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,0.0009877107896219793,0.0012073925449446504
NCT02716077,Early FDG PET in Melanoma,0.0014506744608139943,0.0007930935190388799
NCT02748564,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0011777458049578827,0.001331793941815971
NCT02744209,Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients,0.0011215462733686196,0.0012566967942761005
NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,0.0008942062966660399,0.001162846131237005
NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,0.0010694899134259816,0.0009698288223211252
NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",0.0009090084675305382,0.0013414442351289881
NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,0.0009045778248473938,0.0009035157486555446
NCT02796352,A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,0.0012580072052594063,0.0011936175637349067
NCT02759536,In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma,0.0011120854827781665,0.000910891640399262
NCT02700763,[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis,0.001046154118686621,0.0009679250739915181
NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects,0.0010098714702043807,0.0011991304499332797
NCT03028948,Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma,0.0009829188939002693,0.0009504343213115288
NCT03084640,Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,0.000980630198708729,0.0009110785901008764
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,0.0008698095084275027,0.0009418299294578966
NCT03089606,Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,0.0007344876164087038,0.0007956287340270835
NCT03064763,Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma,0.0009701875472978968,0.0014036512470852883
NCT03034395,Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma,0.0011278788951771424,0.0012560844612138605
NCT03026517,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,0.0010097641425637566,0.0010059315318266188
NCT03007823,High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma,0.0007829719083875825,0.0011973712199023698
NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,0.0011888783254833807,0.001045307599745204
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",0.0010470727943437147,0.001098913448120688
NCT03021460,Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011033362662607234,0.001310701970154028
NCT03068455,An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,0.0009973430288316549,0.0010405439719343378
NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",0.001216238676191707,0.0010113682925382344
NCT03086174,Tolerability and Pharmacokinetics of JS001 in Combination With Axitinib in Patients With Kidney Cancer and Melanoma,0.0010276511320853796,0.001209987648292394
NCT03057327,Promoting Early Detection of Melanoma During the Mammography Experience,0.0008305821095720347,0.0006257390120166562
NCT03012009,Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial,0.000726028687778555,0.0006886922793078829
NCT03073031,The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy,0.001549317511581596,0.0009336951531288098
NCT03069846,"Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope",0.0008357446702401998,0.0004979165431170671
NCT03002376,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1),0.0010931530918723768,0.001165084381909233
NCT03033576,Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,0.0012086642874818193,0.0013815549449015306
NCT03033485,18F‐Labeled Picolinamide PET Imaging of Melanoma Diagnosis,0.0007530133625467887,0.001002980235074085
NCT00203008,A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma,0.001127948347541032,0.0011803276641720124
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,0.000786945626925925,0.0008379620013019778
NCT00255762,"Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",0.0010949188459350458,0.0010767113730844695
NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,0.001027414931323956,0.0011606366711908735
NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,0.0010153125599827986,0.0009537632909848748
NCT00243061,AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma,0.0016953270571029343,0.0013465776817574637
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,0.0010325343272689208,0.0010516798797555185
NCT00204529,Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB,0.0012567989820646977,0.0012044635762234182
NCT00204581,Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases,0.0007694079689551637,0.0009330008007712734
NCT00235482,Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma,0.0010303704032453417,0.0012932977963260287
NCT00278122,Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011796583169918146,0.0012866027246913085
NCT00264056,Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases,0.001070320619186275,0.0011708151473654802
NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,0.0010802051810073893,0.0010383657933127467
NCT00281541,A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma,0.0010835997686373827,0.0014462588355689738
NCT00288938,Natural History Study of Moles and Suspicious Melanoma,0.0008867096670753194,0.0009110831822817932
NCT00294476,"IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma",0.0007943159372906999,0.0012537779744029324
NCT00246012,"A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma",0.000940436484785177,0.001141663011935471
NCT00273910,Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma,0.0007811119568664576,0.0014065239536959202
NCT00217542,Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery,0.0011555994010792137,0.001152753099367907
NCT00232726,Clinical Study of Previously Untreated Patients With Malignant Melanoma,0.0012227394476926493,0.0011651134516404346
NCT00200577,Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma,0.0007792322640206566,0.0009615980662243138
NCT00289640,Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012860539872473584,0.0014726621673034023
NCT00289016,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,0.0011683525530020143,0.001347825271452911
NCT00289627,A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012217539127361374,0.0012164865650443463
NCT00226473,Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma,0.0007483829094943649,0.0010142453647858575
NCT00258687,"Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma",0.0008024159180729464,0.001025604935981358
NCT00257465,"Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",0.0011742837334558682,0.0012434507468364413
NCT00272415,"A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma",0.0011161984328418519,0.0010230336930589572
NCT00287196,Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes,0.0007505044380345377,0.0006673770908193984
NCT02366195,Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma,0.000709051753541993,0.0009884773657208704
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,0.0008597330704801866,0.0008735950769145047
NCT02352623,Quality of Life and Surgical Late Effects of Melanoma Treatment,0.0009525303338209498,0.0011055046293856749
NCT02335476,Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography,0.0008357397886614138,0.0006674602398376891
NCT02332668,"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",0.0009239866990896219,0.0009922919043589408
NCT02310451,Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes,0.0008903801141539483,0.0011000296671815723
NCT02306512,Mohs and Immunofluorescence for Malignant Melanoma In Situ,0.001450674460813994,0.0009641967297739045
NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,0.000931008299879054,0.0011513023056742419
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),0.0009170991928376993,0.0008937329601813959
NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,0.0012247184465026153,0.0011621102114348432
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",0.0008324534629009054,0.0008369555323992757
NCT02375984,A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas,0.0008780624262819928,0.0010106574828202975
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),0.0009596306379877925,0.0010307983567965633
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,0.0011298908474284618,0.0012341264093545226
NCT02385214,MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma,0.0010254661511644248,0.0006885465769621545
NCT02385253,Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance,0.0006971221313598247,0.00047712626727588634
NCT02374242,Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases,0.0012400599833516037,0.001268838861754184
NCT02320058,A Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab by Itself,0.0011602721031417768,0.0011150137688212601
NCT02320305,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,0.0010147952636554442,0.0011675897280217786
NCT02372708,Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy,0.0008641361399942321,0.0007091931295722349
NCT02327390,Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma,0.0011007099817870588,0.0013088911218103424
NCT02318771,"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",0.0010035971892663942,0.0011582083471111586
NCT02302339,A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma,0.0012049180002635176,0.0012620013501431137
NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC,0.0008698095084275027,0.0009317647187789292
NCT02331134,Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,0.0006976922270458515,0.0008354679651773962
NCT02355574,5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results,0.0008000083502531273,0.000652126290654691
NCT02355587,Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes,0.0011281069006354063,0.0008498267457046406
NCT02307149,Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,0.0013674231319198604,0.0014910653008069572
NCT02301611,Phase IIB TL + YCWP + DC in Melanoma,0.0027806170385663203,0.0009204503657260549
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,0.0008394153000977333,0.000798171745371172
NCT02393001,Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques,0.0007012021617723666,0.0008016270220546248
NCT02339571,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011286226155464137,0.0012594731197433885
NCT02339987,Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration,0.0008679065175453601,0.0012453613429869797
NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,0.0010914365223081994,0.0012115987286063718
NCT01308762,"A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients",0.0011148135314423147,0.0013679368899580406
NCT01388569,Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim,0.0011013548344219785,0.0011861673094823901
NCT01336270,"Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients",0.0010903628940007158,0.0010700341345829044
NCT01341158,NAM-Trial: Multiferon in Malignant Melanoma,0.0014506744608139943,0.0008322864009987374
NCT01328535,Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.00115973380633268,0.0013058587386579155
NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,0.0011101390238461802,0.0012850093711543635
NCT01320085,A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma,0.0012263348882039242,0.0012227426271119895
NCT01321437,Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,0.0011639832017818965,0.0014055114391907254
NCT01311466,Liver Transplantation and Uveal Malignant Melanoma,0.0014506744608139943,0.0010310568717173236
NCT01323517,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,0.0008805333422356811,0.0010388663175071307
NCT01356771,Melanoma Risk Assessment & Tailored Intervention,0.00102350747633732,0.0006685224284860619
NCT01302496,Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0011691948187241997,0.0010383898168806788
NCT01355120,THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease,0.0013408441930935612,0.0011048763472846807
NCT01355562,Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer,0.0007463554887457215,0.0009609239311323262
NCT01359956,Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma,0.0008575307821563603,0.0010305708528025159
NCT01397708,Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma,0.0009247024293543963,0.001034657442321752
NCT01338389,Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy,0.000999004220880434,0.0010357314878206756
NCT01316692,Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma,0.0011912066961212895,0.0011456518511679045
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,0.0012546265595773656,0.0012924723777081304
NCT01363206,Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma,0.0008019032762151903,0.0009421650372749694
NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",0.0010340366743235745,0.0013609590164651462
NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,0.0011790250731798155,0.0011720188581971552
NCT00813449,Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma,0.0011895443439593188,0.001034200835633177
NCT00871533,Pilot Study of IFN α2b for Melanoma Patients,0.0017566190876222697,0.0010860592854279342
NCT00811759,Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma,0.0011827372250947318,0.001158349654129045
NCT00816374,Tailored Intervention for Melanoma Patient's Families,0.0015264366594634103,0.0008271298527195473
NCT00831545,"Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)",0.0008532383457219644,0.0009787511056575404
NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,0.001256027080500534,0.001282343316738074
NCT00866840,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011741784185981023,0.001310196772546966
NCT00862914,"Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi",0.0006938885640476665,0.0006349175492216037
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,0.0010752841981202387,0.001046474671817685
NCT00835419,Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression,0.0008972041204234603,0.001398091153475441
NCT00835133,"Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma",0.0009595882006737112,0.0009495358871890507
NCT00861406,Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine,0.0008363540143563783,0.0008766624065524095
NCT00849407,Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma,0.0007379425149291124,0.0007183708166083836
NCT00889980,Melanoma Molecular Profiling Analysis,0.0014551632089041468,0.0007604939676939366
NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,0.0010718859292601398,0.0013254652509749401
NCT00847522,Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma,0.0010146542255085468,0.0010150009060794535
NCT00897520,Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy,0.001087743220857672,0.0011707419162606226
NCT00897481,Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy,0.0011003566340719718,0.0011123593798205008
NCT00897546,Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma,0.0010806410233490337,0.0011457448480829008
NCT00826995,Comparison of Video-Based Versus Written Patient Education on Melanoma,0.0010641458610497702,0.0010814589440916976
NCT00809588,"Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)",0.0007010603191491106,0.0009118146906358305
NCT00841204,Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma,0.0010235355303698662,0.0008211835126689192
NCT00839410,Multicentric Cohort of Melanoma Patients in Ile de France Area,0.0015254536069636586,0.0009021019708956324
NCT00803374,Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma,0.0013178438975186505,0.0016686113835265586
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,0.001118899200345133,0.0011743666106482445
NCT00846833,Haploidentical NK Cell Infusion in Malignant Melanoma,0.0008565839963999751,0.0009526063848680737
NCT01644591,Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases,0.0010027512724634035,0.001050753419223769
NCT01673854,Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma,0.0010641659243904665,0.0015001769511447912
NCT01657591,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,0.0012583474500301429,0.0009667933607344612
NCT01676649,Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma,0.0011815707171463922,0.0010760821426125408
NCT01676779,mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma,0.0009719022450662639,0.001016945737972774
NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,0.0009950807973292189,0.0012479746511719922
NCT01636882,Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks,0.0015702554393064235,0.0012956791183260565
NCT01636960,A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370),0.0012715781005255002,0.0011449393398491033
NCT01666418,Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel,0.0011653367768130586,0.0013216511840702051
NCT01610531,COPARIME: Pilot Study of a Target Detection of Malignant Melanoma,0.0012596359417333604,0.0008448230747106823
NCT01622933,Multiple Antigen-Engineered DC Vaccine for Melanoma,0.0014873101753102827,0.0006622908632409153
NCT01681212,Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma,0.001279629552524573,0.0013466725215608498
NCT01614301,"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",0.0010911298664626938,0.001165264245517547
NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,0.0010718799731053567,0.0014666600598696308
NCT01682083,A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,0.0009396594043670526,0.0010283216416417924
NCT01672450,A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma,0.0011787744030102253,0.0010237256060554305
NCT01677975,"The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma",0.000957787193720492,0.0010973624466539794
NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,0.001450674460813994,0.001212854637176731
NCT01662713,Optical Frequency Domain Imaging for Non-melanoma Skin Cancers,0.0008431496884551688,0.0007981283204655864
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,0.0009049372845361401,0.0011175200844206685
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,0.001239341536860679,0.0011651943513959575
NCT01667419,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,0.001154676137514881,0.000890270545921577
NCT01605162,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,0.0010208912501726661,0.001110287888087152
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",0.0009844839684117973,0.001024587819064573
NCT01616199,Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma,0.0013347279446414926,0.0011558089024508347
NCT01037127,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,0.0009010386092093461,0.0009386714801046124
NCT01052142,Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma,0.001278555015138645,0.0011419552997339263
NCT01082198,Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes,0.0010915337026777556,0.0011077684500541253
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,0.0009646849903066961,0.0010199806631972447
NCT01039844,Study of Weekly LOC-paclitaxel Injection for Melanoma,0.0010134198440528996,0.0010525466415656146
NCT01003626,Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients,0.0012089468274682322,0.001239825779739823
NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",0.0010239917951458536,0.001035840148933079
NCT01026324,Dinaciclib in Treating Patients With Stage III-IV Melanoma,0.0013259253652458435,0.001233374395299677
NCT01067066,A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma,0.0010692074112292533,0.0010575141043418514
NCT01085396,Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin,0.0006801958253355054,0.000707039617144043
NCT01034696,Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting,0.0009815484211172366,0.001065656022122427
NCT01028222,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,0.000981878278921779,0.001425684095154959
NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,0.0007474192566370097,0.001108211039737582
NCT01021059,A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer,0.0008734659852540595,0.001465649212428776
NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0010729155502730977,0.0011223177637710788
NCT01002560,The Identification of Novel Prognostic Markers in Melanoma,0.0008464768268582525,0.0010174719598400165
NCT01077050,SciBase International Melanoma Pivotal Study,0.0017953059295402938,0.0007844320038121558
NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.001176636525993885,0.0011271520169580938
NCT01092585,Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH,0.0010936100999049641,0.0010766481762885351
NCT01092728,"Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",0.0010025854789849856,0.0011909754199889943
NCT01011530,Dose Escalation Study of MLN4924 in Adults With Melanoma,0.0017953059295402938,0.001163795001700632
NCT01009775,A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma,0.001043838878131365,0.0012046077803398137
NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,0.0014104142708894344,0.0011097624958198212
NCT01066390,A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0011773527213763783,0.0012498641988541853
NCT02425475,FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA),0.0010285035143593282,0.0004979115069812303
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,0.0009785851973516339,0.0010282901998213134
NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,0.000977491754268849,0.001024401210109072
NCT02442466,Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma,0.0008902666891278618,0.0008166646031062473
NCT02457065,Skin Care Behaviors Among Melanoma Survivors and Their Families,0.0010235477749062185,0.0007462640101825221
NCT02410733,Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,0.0010679775706925459,0.001361506260328512
NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,0.0008458062864400022,0.0010818515412986218
NCT02437279,Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients,0.0011697757109248425,0.0013164308392285612
NCT02437305,Melanoma Perception and Health Literacy in People of Color,0.000829019476593346,0.0006766174833980624
NCT02437136,Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,0.0009088238293456959,0.0009583915560100242
NCT02492815,"PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma",0.001129948459801036,0.0012680237539522154
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,0.0009678963884339969,0.00119704685751832
NCT02452294,Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER),0.0010740196167903103,0.00103868702537868
NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,0.0012472704350675562,0.0013951546604847602
NCT02470273,Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID),0.0010002984322175729,0.0007799984938109974
NCT02402699,Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan,0.0010897857815157204,0.0007751640099738615
NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,0.001190759013029305,0.0009075717392899899
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,0.0009554080486102951,0.0009807992535779057
NCT02434107,"Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)",0.0009671005031597302,0.0008320621021663118
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,0.0012354639584975105,0.0012094205943400215
NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma,0.0009133191533228978,0.0013342914333133867
NCT02460068,A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis,0.0009727553645119756,0.0010308346148134506
NCT02451488,Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma,0.0007379319590925469,0.000707188503993255
NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,0.0008038784801806877,0.0009410672806014814
NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,0.0011058464237052178,0.001056272562798657
NCT00101166,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,0.0006947823766513398,0.0009067374127257353
NCT00104845,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0012189289542963596,0.0012743721247600584
NCT00104884,FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0012968884073686208,0.0012606331588614066
NCT00104988,S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011158220079344184,0.0011335756693386762
NCT00104897,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma,0.0012622295019288638,0.001136973986990625
NCT00121225,Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma,0.0011404798019075757,0.0012029119704929096
NCT00184067,Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma,0.0010124874961829013,0.001071496894055452
NCT00179608,Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy,0.0011360334477813969,0.0010451617318775858
NCT00110019,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011525265373908081,0.0013345835922620366
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010295307232258107,0.0010662312519948587
NCT00119249,Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011791056756074883,0.0011793821302144957
NCT00142454,NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting),0.0007585682573095988,0.0010358742051560176
NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,0.0011963936714416872,0.0013503380484599524
NCT00109863,Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma,0.0013423988104188686,0.001339612794437055
NCT00160992,Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients,0.0009743908631419853,0.0008895766268480873
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,0.0012249606468531249,0.0012425057793684288
NCT00111696,Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma,0.0011856107094187433,0.0014335869462364422
NCT00128583,Vaccine Therapy in Treating Patients With Malignant Melanoma,0.001580029785806905,0.001267766987825611
NCT00199901,"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma",0.0011478069960083165,0.0012411776451132293
NCT00199342,"A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",0.0012266723167916305,0.0009567784157727713
NCT00118313,"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011702284404613232,0.0012893989880426076
NCT00118274,"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011711915659917429,0.001325989564657
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",0.0008494584730277363,0.0010529841269955947
NCT00112242,Immunotherapy of Stage III/IV Melanoma Patients,0.0013444138817791764,0.0010485032108805028
NCT00112216,Immunotherapy of Melanoma Patients,0.001549317511581596,0.0011023927084332433
NCT00112229,Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients,0.001176676073316054,0.001375340995472493
NCT00153569,Multiepitope Peptide Vaccination in Melanoma,0.0010598452343715695,0.0008384490010667879
NCT00116363,Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma,0.0012107044567339332,0.0015909478831178856
NCT00107159,Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma,0.0012039305717300313,0.0012394455029463326
NCT00108875,"Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer",0.0010552224249318373,0.001208181299430333
NCT00145041,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,0.0010873750792603444,0.0010434541571051105
NCT00126685,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.001382637721689934,0.0011977284794024061
NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,0.001136381633819005,0.0011242163097564474
NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",0.0011517957550167097,0.0010976907386465395
NCT02180061,Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041),0.0011569839542811561,0.0013152755919988105
NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),0.0009690770965373832,0.0009777689976732179
NCT02177110,A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma,0.0008555651099381312,0.0010024661874783293
NCT02112032,Treatment of Advanced Melanoma With MK-3475 and Peginterferon,0.0010194463454896007,0.0011041901354831001
NCT02166255,"APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",0.001051182320731317,0.001187863838376246
NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",0.0009980356594904063,0.0010703228902020389
NCT02147951,"Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",0.0008771919781672882,0.0013478161639006354
NCT02193581,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.000700465897598738,0.000697272059095453
NCT02106598,"Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Gynecologic Malignancies",0.000683261399450662,0.0009538494875006617
NCT02129075,CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,0.0011218373385978714,0.0012559045324990498
NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,0.0010373905477269383,0.0013221925067812522
NCT02190838,Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma,0.0007189260022178392,0.0008426636282617133
NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,0.001306291923999902,0.0012454251218448368
NCT02158520,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011214315060719146,0.0013420229835864176
NCT02156804,"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",0.0008834388411938862,0.0010339669734503133
NCT02196181,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,0.0011089834731509824,0.001266780736262999
NCT02155322,A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400),0.0010806883276158691,0.0017606414854579382
NCT02115243,Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,0.0010314585159899392,0.001148088625314615
NCT02115139,GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases,0.001151355845020857,0.0011763739589610463
NCT02142218,Expanded Access Program With Nivolumab to Treat Melanoma,0.001053981536689706,0.00112803204765451
NCT02142335,Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma,0.0011179554297118066,0.0012932328912789476
NCT02142244,Fluorescence Surgery for Sentinel Node Identification in Melanoma,0.0008906212610314236,0.0007359396685505555
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,0.000995984104026752,0.0011747755911873596
NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,0.001155631475897031,0.0010774042237319667
NCT01174238,A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852),0.0008385695929697334,0.0009476520377360843
NCT01120275,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,0.0013410082663136938,0.0011607175381920622
NCT01106040,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,0.0008402910296866333,0.0006022286956435868
NCT01127594,Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion,0.0009870737912797399,0.0012308724609854163
NCT01127451,Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma,0.0012432024771663866,0.0013206771589522777
NCT01189383,"IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",0.001172445330970641,0.0012989556555395012
NCT01183936,Trial of Surgical Excision Margins in Thick Primary Melanoma,0.0010981160428792706,0.0009703477676252675
NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,0.0012775123556503605,0.0011249696310463148
NCT01133977,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,0.001072896594356556,0.0008664159869650838
NCT01191294,Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma,0.000712476766344702,0.0005044220158369416
NCT01121718,NIR-Guided Sentinel Lymph Node Mapping in Melanoma,0.0010256277953816428,0.0007710866882357538
NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,0.0008789916765492706,0.001128305532882965
NCT01134614,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0012005338303807027,0.0011480516464995626
NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma",0.0013960433020958234,0.0013093249511811806
NCT01124734,High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma,0.0009928032381554964,0.0009987059888093555
NCT01118832,Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi,0.0007182398136891498,0.0005841702104057352
NCT01168050,Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.,0.0008688167071419462,0.0008874720307866774
NCT01176474,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,0.0010444419742262371,0.0010283695392124903
NCT01136967,"An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",0.0010062672974826706,0.0011265026205840494
NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),0.0008382695171781594,0.0009543183812267278
NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,0.0027806170385663203,0.0012981875483901672
NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,0.0008921435934362556,0.0009108004850609643
NCT02068196,A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.,0.0013674231319198604,0.0009794253309972395
NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma,0.001331320138712174,0.0011982483238814296
NCT02009384,Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox,0.0008748013162417502,0.0009689812965771766
NCT02009397,A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,0.0012549320468820716,0.0012258144429041654
NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma,0.001253328434595792,0.0013226775285368416
NCT02094391,"Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma",0.001124950705954711,0.0009249683437987786
NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,0.0012632511187584093,0.0011572692543421364
NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,0.0008699177135573033,0.0011356024662706765
NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,0.0008597577752817702,0.0009819539852899343
NCT02056522,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.000700465897598738,0.000697272059095453
NCT02074605,Cognitive Effects of Interferon in Patients With Melanoma,0.0015382610604970169,0.0009692951946176283
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,0.0012326036945408238,0.0013387370430247762
NCT02029729,RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER,0.0008685966467574301,0.001024734478039162
NCT02058953,"CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases",0.001035839752197983,0.0009734623812293943
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,0.0012385912795103953,0.0010525385600839107
NCT02088762,Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm),0.0012202980582012072,0.0007306467776334743
NCT02077114,Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma,0.0009141277126558917,0.001054777789885099
NCT02097732,Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,0.0010487178305453946,0.0011575817991851794
NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,0.0008296813966024378,0.000979076724321265
NCT02020707,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers,0.0010888319951159486,0.0012507880741642282
NCT00938223,"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma",0.00106622847465499,0.001047237514087581
NCT00928902,"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma",0.0009920008677582767,0.0010527490142830712
NCT00945269,"Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",0.0010767077065372609,0.0011019813591908042
NCT00942162,A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma,0.0012503980409371042,0.0012282637126191794
NCT00936221,Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients,0.0010112340872452652,0.0009709471512749617
NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,0.0012457421121835183,0.0013278954359112177
NCT00966173,International Melanoma Algorithm Training Study - IMATS,0.001011539208607454,0.0007554837678320482
NCT00920907,Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma,0.0008413865262717755,0.0010635066355953067
NCT00972933,Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma,0.0008136172499414113,0.0010511592040581951
NCT00901966,Sun Exposure and Melanoma in Agricultural Workers,0.001452144016887707,0.0006927103043924129
NCT00963664,Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma,0.0008163430263876863,0.001183567522452473
NCT00963261,Quality of Life and Psychological Well-being in Patients With Malignant Melanoma,0.001215559211482184,0.0011201523660148115
NCT00923169,Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma),0.001220185747471595,0.0013717481505651325
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,0.0011370533357176055,0.001325302928492137
NCT00979693,Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma,0.0008414575753306054,0.0007591545898373369
NCT00940004,Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients,0.0010901699668478288,0.0011001554420685816
NCT00977145,Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma,0.0010115050382463928,0.001173207434961704
NCT00974610,"Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12",0.0011639927450699161,0.0009385533673242699
NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",0.0010035771100934605,0.0010069217485957072
NCT00912730,A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma,0.0008924706091816169,0.0009015397753707583
NCT00912418,"Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma",0.001148467339092736,0.0010207801629390151
NCT00912574,Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38,0.0009789819407580724,0.000983149948189839
NCT00961844,Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma,0.0011525467516741018,0.0009444661841950791
NCT00961376,Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC),0.0010143273652031147,0.0012196788759989896
NCT00925314,A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma,0.0009879419562457904,0.0008546538857633634
NCT00962845,Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011746937428472146,0.0010708877217566889
NCT00991250,SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma,0.0010194463454896007,0.0015416914796990235
NCT00991991,"Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma",0.0011991190534010145,0.0012595783937547865
NCT00911443,"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma",0.0010288432509546791,0.0011714699758492704
NCT00937625,T-cell Based Immunotherapy for of Melanoma,0.0014857461781472014,0.0011988762400577842
NCT00937781,Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690,0.0011618157937619777,0.0012270864219097893
NCT00937937,Dinaciclib in Treating Patients With Stage IV Melanoma,0.0013417219404590621,0.0012678394278436646
NCT00071981,Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma,0.0010127055191006711,0.001120288559748302
NCT00028431,Novel Adjuvants for Peptide-Based Melanoma Vaccines,0.0010641189830504962,0.0009304877023485899
NCT00017121,Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.0010317495423606458,0.0012239210574242726
NCT00006035,Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011608697479430865,0.0011920693035540823
NCT00006126,"Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",0.0010238065357661623,0.001208426930925553
NCT00006243,Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma,0.0012078463879711084,0.0013144991171629974
NCT00006237,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,0.001227850895543827,0.0010119115829944681
NCT00006022,Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer,0.0010769542058736963,0.0012584875923907458
NCT00006113,Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011962940495886425,0.0012685678835518363
NCT00006233,"Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma",0.001038784419517607,0.0012365725703231698
NCT00006249,Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma,0.001202049442466519,0.0011132503987872004
NCT00084214,STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma,0.0010470400008538063,0.001418346732087512
NCT00084656,Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma,0.0011604812777379207,0.0012162058938809126
NCT00042783,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.001382637721689934,0.0015019049621055754
NCT00042497,Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma,0.0011883155442099125,0.001167905009619787
NCT00087386,Tanespimycin in Treating Patients With Stage III-IV Melanoma,0.0013259300062825618,0.0010964967516724992
NCT00087477,A Pilot Study of Pivanex in Patients With Malignant Melanoma,0.001390899131196999,0.001289999641649266
NCT00087776,Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma,0.0011361919058788025,0.0011131977338097799
NCT00083239,Study of Talabostat in Advanced Melanoma,0.001417021230515079,0.0017003003762840203
NCT00083252,Study of Talabostat and Cisplatin in Advanced Melanoma,0.0011343900297219277,0.0013489673061536742
NCT00033228,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.001382637721689934,0.0014002484177848993
NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,0.0014036726662422804,0.0015841799293408192
NCT00060125,Tipifarnib in Treating Patients With Metastatic Malignant Melanoma,0.001262243223054241,0.0012442903280280707
NCT00016263,Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma,0.0010970853031007381,0.0010812837227506982
NCT00010309,"Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",0.0011995517672483517,0.0014169960793336699
NCT00085397,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.0012285977350513025
NCT00085189,Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma,0.0012885942116524587,0.0014256206472371533
NCT00085488,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.0012743721247600584
NCT00085579,Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011396120370772715,0.0010832769158582456
NCT00074308,Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers,0.0010681597473339301,0.0012535370051520215
NCT00014625,E7070 in Treating Patients With Stage IV Melanoma,0.0013410082663136938,0.001425644344718243
NCT00014092,Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery,0.0011293915991280549,0.0014055743453636504
NCT00049530,PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma,0.0013410082663136938,0.001241769829706955
NCT00025181,Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery,0.0011803410570237023,0.0013981971978196202
NCT00003091,High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma,0.001020632130725427,0.0011486860102156553
NCT00003266,Methylphenidate in Treating Patients With Melanoma,0.0015254536069636588,0.0009392241745045026
NCT00003646,Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.001257787567429618,0.0015095624103189191
NCT00003509,Antineoplaston Therapy in Treating Patients With Stage IV Melanoma,0.001220072822999893,0.0010835796043884005
NCT00003641,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,0.0010923996269173771,0.001055210821223879
NCT00003911,S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases,0.0007289472249877016,0.0009522638914533188
NCT00003346,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012571947627902406,0.0013365276077107703
NCT00003308,"Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma",0.00099302327693595,0.0011282326466580178
NCT00003647,Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011851955536332664,0.001210285491534519
NCT00003556,Vaccine Therapy in Treating Patients With Melanoma,0.001580029785806905,0.001422789603062541
NCT00003715,Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma,0.0011920239294098453,0.001129582259715304
NCT00003789,Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg,0.001056629418466168,0.00095826386571904
NCT00003897,Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma,0.001104571782514303,0.001357537938270991
NCT00003444,"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin",0.0009703694664275934,0.0009535152783487689
NCT00003895,Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma,0.001266639462623262,0.0012228365833767242
NCT00003222,Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012027361602541134,0.0013535841670002618
NCT00003828,S9804: Vinorelbine in Treating Patients With Stage IV Melanoma,0.0013417718367264744,0.001312937282721421
NCT00003665,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.001382637721689934,0.0013967562948143113
NCT00003362,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,0.0012091086352221494,0.0013294208940759352
NCT00003339,Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma,0.001198152854150794,0.0012614233947678922
NCT00062491,Study of Karenitecin (BNP1350) to Treat Malignant Melanoma,0.0012546513422228497,0.001904998818726588
NCT00091689,Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions,0.0007890364658296889,0.001087058099865754
NCT00057616,Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.,0.0009305829978872077,0.001021604273129643
NCT00055562,Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma,0.0009262574764664286,0.001014655115053014
NCT00040352,"Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma",0.0008482800370724018,0.0009558159707951573
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,0.001317288327958129,0.0010762508407326215
NCT00077532,Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma,0.0010571623875873612,0.0011587343007241108
NCT00053391,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.0014367791720389237
NCT00023647,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.001382637721689934,0.0013824531247728792
NCT00039091,"Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",0.000956373756384835,0.000861993946712149
NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,0.0009061075312893709,0.001012757283422646
NCT00039234,Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver,0.0010830021303642955,0.0010587542538442623
NCT00039572,Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain,0.001029985815178078,0.0011815342460248022
NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,0.0013668411464767155,0.001236554764591434
NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,0.001382637721689934,0.0011813104191464186
NCT00059800,Boron Neutron Capture Therapy in Treating Patients With Melanoma,0.0015283560132706227,0.0013563272959692331
NCT00027742,Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma,0.0011826383056001515,0.001395651682398444
NCT00072163,Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma,0.0010286933081701717,0.0010755989986566622
NCT00072124,Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma,0.0010954268324745238,0.0011288146818827975
NCT00072345,"Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma",0.0011503298412454753,0.0013735077997735839
NCT00020358,Vaccine Therapy in Treating Patients With Melanoma,0.001580029785806905,0.0014163270579742257
NCT00020839,Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain,0.0011077492413257611,0.001031614076897189
NCT00068172,Study of PI-88 in Patients With Advanced Melanoma,0.0015156893716673984,0.002073361590508586
NCT00068666,Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System,0.0010848694199386876,0.0010559806081488995
NCT00036764,BMS-247550 in Treating Patients With Stage IV Melanoma,0.0013410082663136938,0.001425644344718243
NCT00002980,Decitabine in Treating Patients With Melanoma or Other Advanced Cancer,0.0010676853855531901,0.0013785290823237733
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",0.001045142524097919,0.0010966826026140527
NCT00002763,High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma,0.0011140347681458768,0.0010498426294381046
NCT00002781,Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma,0.0013278608574387738,0.001322276378476126
NCT00002973,Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma,0.0010887779847724734,0.001281535454045483
NCT00002882,Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,0.0010762509629387556,0.000992243939009373
NCT00002535,Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma,0.0011671843254276403,0.0012254884048754058
NCT00005057,Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma,0.0011661621375133838,0.0012258908391999763
NCT00005617,Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma,0.001200864214665688,0.001392180056478698
NCT00005815,Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma,0.001179832297502909,0.0013633619474490808
NCT00005633,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.0012743721247600584
NCT00005610,Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.0011274002521228135,0.001147414005994578
NCT00005968,Irofulven in Treating Patients With Stage IV Melanoma,0.0013410082663136938,0.001425644344718243
NCT00005841,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.0012760749269913397
NCT00005971,Flavopiridol in Treating Patients With Metastatic Malignant Melanoma,0.0012615158311324343,0.001357547968069291
NCT00005949,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,0.0011914190780380105,0.0013555099181369369
NCT00086866,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery,0.0012055534497163339,0.0012174877142862724
NCT00086489,"CP-675,206 In Patients With Advanced Melanoma",0.0016888263864463142,0.001547238515356334
NCT00004244,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma,0.0010385214039741954,0.0010180092766424273
NCT00004135,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer,0.001037903076364059,0.0012138573290113573
NCT00004022,Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma,0.001201854373738431,0.0014850236776760952
NCT00004250,Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery,0.0010025666673708121,0.0009463115222995555
NCT00004104,Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma,0.0011147633363019988,0.0011163448391806224
NCT00004184,Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012584834428911956,0.0012523425879865558
NCT00004153,Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma,0.001008028127034187,0.0007975146968519962
NCT00004152,PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma,0.0011318904292502345,0.0010297654082684527
NCT00004025,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012027361602541134,0.0015029583133871216
NCT00004196,Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis,0.0010832444593344827,0.0012087750037785483
NCT00080353,Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma,0.0008929797415004909,0.0014653728308602028
NCT00024011,PS-341 in Treating Patients With Metastatic Malignant Melanoma,0.0012622376600998203,0.001357867593975013
NCT00001296,"A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma",0.0010408616081256066,0.0008323304098947766
NCT00001685,"Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",0.0009960033305773366,0.0011371907716106438
NCT00001439,A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant,0.0008914711728120037,0.0009769514803843477
NCT00001577,Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity,0.0008374285232152305,0.0007240266114160503
NCT00035165,EPO906 Therapy in Patients With Advanced Melanoma,0.0014036726662422804,0.001292489691989479
NCT00007969,Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012566100364238152,0.0013541720031436716
NCT00026520,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,0.0011742814086986933,0.001310215789892803
NCT00026221,Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011129491545309401,0.0009751656159117005
NCT00026143,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011091278138632265,0.001236740362543023
NCT00056134,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.0014640685864671038
NCT00098553,Everolimus in Treating Patients With Stage IV Melanoma,0.001342467703558247,0.0011309993149215393
NCT00089193,"Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0011793502242064535,0.0011463235086058854
NCT00089219,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",0.0012275156064655162,0.0012696653719815316
NCT00089063,Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma,0.0011474744943551659,0.001099466506131992
NCT00089206,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0012055534497163339,0.001259130881777685
NCT00073892,PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma,0.0012822077864820417,0.0014142650312647142
NCT00032045,Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.0012021413146809379,0.0012588771361730397
NCT00090896,"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",0.0011483688276624853,0.0012832484534821425
NCT00031733,Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma,0.0010163038755371956,0.0010934171291139062
NCT00095108,Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer,0.0009438478789359308,0.0009781853701492109
NCT00070642,CPG 7909 Injection in Melanoma,0.0014608344511098706,0.0012604080419500812
NCT00070343,Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301,0.0011115444390380504,0.0011528797086344331
NCT01456104,Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma,0.0010013437109948203,0.001114250960748704
NCT01496807,Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma,0.0008693884604397539,0.0010058192732007101
NCT01460875,Recombinant Interferon Alfa-2b in Treating Patients With Melanoma,0.0015362015838048491,0.0015087844887051143
NCT01425749,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,0.0008999862273150926,0.0010586842385781152
NCT01409733,TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients,0.0009876030773003945,0.0011048429798386755
NCT01489423,Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim,0.0011584321100287973,0.001206380364110486
NCT01489059,Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma,0.001113057433350851,0.001051409256304577
NCT01433991,E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),0.0009910406193445536,0.001122940612886754
NCT01482260,Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma,0.001450674460813994,0.0010957930324488785
NCT01480154,"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",0.0010628215057022499,0.0012162321224336162
NCT01444560,"miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi",0.0007478199587426558,0.0006572727197630791
NCT01495572,Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells,0.0008403993797790265,0.0010745756387524332
NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,0.0011111236414662344,0.001116795319643046
NCT01432860,A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination,0.0009981278610921409,0.0006411983359800591
NCT01462773,"Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",0.001165055314202604,0.0010781463056045322
NCT01453361,Phase II FANG™ in Advanced Melanoma,0.0011858813009265569,0.000964120051338789
NCT01469455,DNA Repair Inhibitor & Irradiation on Melanoma,0.0008536572710317405,0.0011034846176684538
NCT01449279,Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,0.0010208304292665452,0.0009037940557662209
NCT01435499,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,0.00113194792103004,0.0012534939436938293
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,0.001354659504729088,0.0011256432330503106
NCT01455259,Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors,0.0009394819901604022,0.0009856874257923721
NCT01455103,Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma,0.0011457397335488417,0.0014261467095861456
NCT01295931,Nuclear and Near-Infrared (NIR) Imaging in Melanoma,0.0014670988437793836,0.0006591579988876946
NCT01295827,"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",0.0009321533394873409,0.0011409810617983988
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,0.0014088633094944134,0.0013097842671811876
NCT01253096,Intratumoral Application of L19IL2 in Patients With Malignant Melanoma,0.001527507418945695,0.0015012933908184613
NCT01213732,Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma,0.0009191896413045425,0.00089075586652549
NCT01266096,PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study,0.0010983701212876865,0.0010595848938816982
NCT01259934,Nordic Adjuvant IFN Melanoma Trial,0.0027806170385663203,0.0010666197466051807
NCT01288963,"IL-2 ""SELECT"" Tissue Collection Protocol in Patients With Advanced Melanoma",0.001092638019673441,0.0012190290556854068
NCT01227551,A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma,0.0013424570415771335,0.0012597532733350449
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,0.0010954573481460842,0.0010352403688922219
NCT01216696,Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,0.001144581169100085,0.0011236822589987066
NCT01216787,"RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery",0.0011688593680328808,0.0012914147944331112
NCT01256359,Docetaxel With or Without AZD6244 in Melanoma,0.0014551625434514974,0.0012404906461552104
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,0.0009006397272288247,0.0009989719545912025
NCT01245556,Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma,0.0010782693477701904,0.001369293488176407
NCT01280565,A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit,0.001334322959925873,0.001050606977585952
NCT01281722,Role of SLURP-1 in Melanoma and Melanoma Stem Cells,0.0008541225436647652,0.000819051056947027
NCT01239134,Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,0.0009858096297816598,0.001050794065449197
NCT01211262,Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma,0.0008886832835049718,0.0009999176755155737
NCT01205815,Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment,0.0012887357435099598,0.0010987834413478488
NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,0.0011314944274907236,0.0013355502763156496
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,0.001126432520489862,0.0013162202974164924
NCT01209676,IMCgp100 in Advanced Unresectable Melanoma,0.0010049726611243367,0.0007854543833531629
NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,0.0007192994887835646,0.0008627195137609428
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,0.0011923798381084651,0.0011968874888186609
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,0.0012188541814464953,0.0009834286419660653
NCT01258855,Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.001089377496150178,0.0012728567822927785
NCT02941744,A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases,0.0007424844799072844,0.0008348709569452641
NCT02990416,A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,0.000844061401732983,0.0009499674215870881
NCT02990611,Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma,0.0011788076288853264,0.0011406575811842938
NCT02917473,Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma,0.0009424782805569791,0.0008835828211983586
NCT02907827,Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.,0.0009945573621090301,0.0006766427817482528
NCT02907086,Circulating Tumor Material in Colorectal Cancer and Melanoma,0.0010707292934387866,0.0010499956728217902
NCT02975700,A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma,0.0012895079976448798,0.0013334709273685615
NCT02938728,Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma,0.0008255752707654461,0.001274467486667306
NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,0.0009467911696560403,0.0011053244804323035
NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,0.0010378430004232596,0.00099332238660356
NCT02970981,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,0.0012156839332141771,0.001356257920666598
NCT02909348,Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab,0.0011359357405222768,0.0010356544918157411
NCT02939300,Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,0.0009160312446742598,0.0010658100408045686
NCT02994498,DCB-BO1301 for Advanced Melanoma,0.0016950164514479508,0.001291186448001434
NCT02978625,Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,0.0011043650508934435,0.0012561015791768468
NCT02905266,A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma,0.0008979130222546564,0.001015318294778054
NCT02989064,"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",0.001043318500156485,0.0009021654241663066
NCT02965716,Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.001350757255090313,0.001349743420057343
NCT02962947,MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients,0.001221472801017649,0.0011594375063615774
NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,0.0010107063676764506,0.0009544502965151353
NCT02993315,Melanoma Patients Immunized With Natural DenDritic Cells,0.0015539525943304242,0.001119990274427082
NCT02915666,A Clinical Trial of Patients With Melanoma,0.001535239024418498,0.001118366939581017
NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,0.0010176812571289313,0.0011122329538939138
NCT02910557,Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection,0.0012089468274682322,0.0010997191064637426
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",0.0009544046968737695,0.000984628711533946
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,0.000979244068103486,0.000936914568144257
NCT02507947,SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access,0.0010952958611251899,0.0010065034484882751
NCT02507076,Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma,0.00102174541834738,0.0011411374824440497
NCT02519322,Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,0.0011325216428119975,0.0011615994376428867
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Hodgkin Lymphoma or Other Solid Tumors",0.0008208393409202864,0.0007919744428923804
NCT02508909,Videoscopic Ilioinguinal Lymphadenectomy for Melanoma,0.001452150271968616,0.0006733531646207454
NCT02545075,A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine,0.0008548790527307562,0.0010221853972497389
NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),0.0010984054064600277,0.0010747780046026815
NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,0.0008108798475041281,0.0011376001283883662
NCT02511119,Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma,0.0006977459217521366,0.0007496417349992273
NCT02574377,myDC/pDC in Stage III Melanoma Patients,0.001674264175960438,0.0012042961925416856
NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,0.0010134826262463551,0.001254917902857907
NCT02509598,"A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping",0.0010958116539715643,0.0009380102599071666
NCT02565992,Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma,0.0011569839542811561,0.001014876697583309
NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,0.001146969826987278,0.0013297473046407775
NCT02506153,"High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",0.001129284585913425,0.0011220641208511775
NCT02581228,"Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy",0.0011445056319496338,0.0011056108306193055
NCT02562625,Trial of Pembrolizumab and Radiotherapy in Melanoma,0.001079743931684593,0.001093484656089651
NCT02575404,GR-MD-02 Plus Pembrolizumab in Melanoma Patients,0.0015588839018916762,0.0019083057118679289
NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",0.0008984116020433737,0.0008159102818800366
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,0.0008693020090294141,0.0008206194795795915
NCT02587650,Trial of TKF Inhibition in Unresectable Stage III/IV BRAF/NRAS WT Melanoma,0.0009939066862620098,0.0010816152362126536
NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,0.0007256920291093515,0.0010409543708744034
NCT00626405,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,0.0010973022679632487,0.0011267550430104501
NCT00626860,The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma,0.0011292625902603558,0.0013981838211031634
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,0.0016888263864463142,0.0012541621752000724
NCT00667901,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011741784185981023,0.001310196772546966
NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",0.0009682661286009274,0.000671331253822726
NCT00667953,Study of Temzolomide and Gleevec in Advanced Melanoma,0.0011314535657400272,0.001178501224064452
NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,0.0008205885640261038,0.0014479810764670175
NCT00636168,Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma,0.0009147675713968899,0.0008399969631305328
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",0.0009559480363721016,0.0009560124066320661
NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,0.0008796631500592008,0.0011848287815633535
NCT00610857,Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma,0.001109492582381466,0.0009630727365053076
NCT00625768,Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma,0.0011610233845019088,0.001176136621706188
NCT00683670,Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma,0.0008743239013399082,0.0010878460381908144
NCT00665470,Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma,0.0007615356344898975,0.0012961632352797541
NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,0.0008080107499795299,0.0010365102037614546
NCT00672321,"Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma",0.0009965995691376339,0.0007265068546110281
NCT00669019,Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011732822464581103,0.0012116608919885904
NCT00658892,Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.0013439041708553873,0.0009168052486178836
NCT00658437,CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy,0.0010240026608713802,0.0012342222236955565
NCT00651703,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,0.0010902235171519775,0.0011995401356985345
NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,0.000995278639604444,0.0011892273267602083
NCT00612664,"Phase II, 2nd Line Melanoma - RAND Monotherapy",0.001456732981460942,0.0011472587403202523
NCT00675727,Safety Study of CADI-05 in Patients With Advanced Stage Melanoma,0.001342784754724427,0.0012503027277393469
NCT00688090,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.,0.0010164000551597559,0.0010675211678353382
NCT00601861,Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer,0.0007574823783586252,0.0007361784280859252
NCT00661336,A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma,0.0010582653548044324,0.0010448649014476604
NCT00602576,Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma,0.0010789808020298067,0.001058454946541346
NCT00615095,Differential Risks for Melanoma: p16 and DNA Repair,0.0014521842963589704,0.0007824602986042925
NCT00615160,PTK/ZK in Disseminated Malignant Melanoma,0.001452225137569271,0.0009463206375115603
NCT00698100,"Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines",0.0011004629946739534,0.001018116614705302
NCT00671554,Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma,0.0010294280070528813,0.0010898855405707193
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,0.000705576147319586,0.0006299720048280428
NCT00398073,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0012189289542963596,0.0011976577325944042
NCT00349206,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.0010646708768091663,0.0010585030327336148
NCT00306553,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.0011135764608269957,0.0012292468660368011
NCT00306566,Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients,0.0010931626532590187,0.001130418508359772
NCT00306514,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.0011135764608269957,0.0012109727586821332
NCT00358319,Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma,0.0010235273341016218,0.001047395468970473
NCT00383292,A Study of LY573636 in Treating Patients With Malignant Melanoma,0.0017566190876222697,0.001318943218406523
NCT00383851,Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma,0.0009770587749197831,0.0011417236533412857
NCT00328861,Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer,0.0008595788427646653,0.0013916295314774145
NCT00346008,Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members,0.0015273981475889217,0.0008552047935538522
NCT00368615,Characterization of the Melanoma-Specific Immune Response,0.0008535768535227705,0.001025227678225753
NCT00370136,Sentinel Node With Ultrasound Contrast in Melanoma,0.0008319821136020696,0.0005380733556441006
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,0.0014566617481997608,0.0008811083882361407
NCT00348088,Melanoma Biomarker Study,0.0012724056765496424,0.0009264899397743202
NCT00304200,Temodar and Sutent as Therapy for Melanoma,0.0008961876323137732,0.0009807256813784478
NCT00397982,Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.0011692978794685172,0.0010348565632781635
NCT00394134,Targeted Intervention for Melanoma Prevention,0.0010255391759237547,0.0007038046159658571
NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,0.0010748111154761089,0.0008965121047640807
NCT00356460,Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma,0.0012566520385435664,0.0009191878948768523
NCT00313235,Combined Modality Treatment for Patients With Stage IV Melanoma,0.0013432788564056854,0.001274683191811333
NCT00387751,Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011620282178723671,0.0010581721980167278
NCT00391300,Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions,0.0009613753905446815,0.0007472052019145128
NCT00341991,Molecular Epidemiology of Cutaneous Malignant Melanoma,0.0010260003060816043,0.0007452171309704432
NCT00357461,Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma,0.00125215398366095,0.001220228727849988
NCT00395070,A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma,0.0011763102668578447,0.0011524246162728149
NCT00300612,Vaccine Treatment for Advanced Malignant Melanoma,0.0010389351988512997,0.0014103599137531343
NCT00390338,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012913147946329183,0.001239642781220278
NCT00317759,Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma,0.001166330423035325,0.0013265768290736046
NCT00327600,Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma,0.0009721512195842663,0.001068921767160635
NCT00339222,Family Study of Melanoma in Italy,0.001450674460813994,0.0007373341648604802
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,0.0008453180290719872,0.000982025896622066
NCT00324727,Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma,0.0010240954758266138,0.0010787558814212112
NCT00323206,Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma,0.0010304124789648685,0.0010393550400663672
NCT00791271,Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion,0.0008410479120822648,0.0009045272489574585
NCT00723710,Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600),0.0011167709160003671,0.0010004495192199232
NCT00794235,Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine,0.0008526182187066513,0.0009606203064166032
NCT00790010,Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma,0.0011555879616523932,0.0011330020060796285
NCT00746746,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,0.0009297484025273668,0.0009742173319785189
NCT00749684,Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083),0.0009015603298686098,0.0008399409528782767
NCT00716495,"Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma",0.0009944404673770508,0.0010285886845124359
NCT00726739,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0012055454631553805,0.001184990520613833
NCT00733798,A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma,0.0013938672884219723,0.0015917903241406193
NCT00700882,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",0.0011097420075669533,0.0010447405449070107
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,0.0010127195654028771,0.0011168323211092133
NCT00796445,"A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",0.0011416426055973017,0.0011297866898773799
NCT00707161,Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma,0.0008491644580987853,0.001121324213143781
NCT00788775,"Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma",0.000989278777835628,0.0009441874242001895
NCT00755976,Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma,0.0010994177324062976,0.0010593927653625326
NCT00706992,Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients,0.001242674049208038,0.0014196897123366248
NCT00722098,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,0.00118073775283114,0.0011873543807899474
NCT00776945,Feasibility and Functionality of fPAM Imaging in Melanoma,0.0010349663060474938,0.000655186440136908
NCT00743496,"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",0.0007411391067737418,0.0009480044197633531
NCT00705640,Vaccine Therapy in Treating Patients With Advanced Melanoma,0.00137955319269738,0.0012692683273180113
NCT00729950,Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011240865049909226,0.0011904215157741741
NCT00445783,Study of Families With Melanoma,0.0017953059295402938,0.0011079809647724821
NCT00466687,Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma,0.0011725386915759002,0.0009822474725629383
NCT00477906,M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma,0.0010494899635695553,0.0013569889079651522
NCT00450255,VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011732822464581103,0.0010934795663157673
NCT00450593,Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma,0.0012138990126982039,0.0011074400533775948
NCT00457418,High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2),0.0011414753305496704,0.0011477340639444616
NCT00492505,"Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",0.0010494117396877246,0.0010476178727722026
NCT00412828,A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010413044197506963,0.0009984892728972137
NCT00409383,Abraxane and Temodar Plus Genasense in Advanced Melanoma,0.0008450165382404075,0.0009957549736038023
NCT00429312,A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma,0.001006699631991578,0.0013994314599017287
NCT00472459,PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer,0.0007400038492535206,0.0009516052228964873
NCT00463892,High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes,0.0007138696683849316,0.0009441766124108063
NCT00424515,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,0.0012160855064325673,0.000930796285770278
NCT00436605,Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma,0.0011741170693049196,0.0011539933209967935
NCT00462280,Lovastatin in Treating Patients At High Risk of Melanoma,0.0012190830944631885,0.0014043453205122294
NCT00462423,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",0.0011753846494179598,0.001072003387360124
NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,0.0010830054026955917,0.0011420341274322233
NCT00447356,High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma,0.0010877193894412356,0.0009544948284341989
NCT00406900,Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma,0.0007906291989420267,0.0009455924012781965
NCT00432107,A Study to Assess APO866 for the Treatment of Advanced Melanoma,0.0011971873192124596,0.0011118269235870489
NCT00432471,Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers,0.0010306925376944809,0.0008000524799045481
NCT00416988,Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants,0.0007440186104337324,0.0005745273441856954
NCT00404235,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011478494843691724,0.0011178792915362062
NCT00470015,"Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",0.0011439977136714868,0.001167739366475828
NCT00470379,"Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",0.0011767611463266128,0.0011762716795588935
NCT00470470,Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.001173699029744132,0.001211952296317965
NCT00438984,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma",0.0010914546580849994,0.0011811449564684624
NCT00438009,A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients,0.0013916336145978405,0.0009858807822529653
NCT00471133,Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation,0.0008375624634795547,0.0008590533238057367
NCT00471887,"Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",0.0011928087996463347,0.001041168315431016
NCT00471471,Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0012055534497163339,0.0011506175169380326
NCT00498979,"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",0.0008200760251749834,0.0009062809110219497
NCT00498836,"Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",0.0010277446000962198,0.0007856413401704379
NCT00453050,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,0.0011009945289482256,0.00111311168251193
NCT00482105,Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells,0.0006982617414972305,0.0006352399629774386
NCT00495066,Compassionate Use Trial for Unresectable Melanoma With Ipilimumab,0.0009434907191219429,0.0009930209692998095
NCT01886235,Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery,0.001039772479359057,0.0012198370645360318
NCT01840527,Utility of Novel BRAF Test for Melanoma,0.001457976490902592,0.0009179118155166283
NCT01840007,Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma,0.0012566248648204447,0.0009686366893191015
NCT01888081,A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma,0.0008530543788197374,0.0010385155800105449
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,0.0010332982648227202,0.0010370631910456005
NCT01864538,A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma,0.0011457397335488417,0.0011806748266687244
NCT01826448,"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",0.0009438146657020569,0.0009500521778685291
NCT01826864,Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma,0.0010213147792078761,0.0013118542043002903
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,0.001020878496809825,0.001155588631463145
NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",0.0011553437165057105,0.0013605244018451033
NCT01897116,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,0.001186247472062979,0.00158908166600063
NCT01867619,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.0010820641915710652,0.0011037720875822392
NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,0.001086305400185845,0.0012027440150307002
NCT01878396,Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors,0.0011178626803743457,0.001373030108302034
NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,0.0009980356594904063,0.0013969973678346838
NCT01859845,Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma,0.000680654622494767,0.0006903082317346841
NCT01866319,Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006),0.0009738687011886934,0.0009964930477868318
NCT01844505,Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067),0.00096695165527262,0.0010941271524963628
NCT01898403,Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma,0.001064881166919311,0.001064390363730991
NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,0.0013192582131428818,0.0010246262553214765
NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,0.0010569880071862544,0.0012096121914935874
NCT01851408,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.0010646708768091663,0.0010585030327336148
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.00113386964173107,0.0011756327438045564
NCT01920516,Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment,0.0008044524330751924,0.0010725623515084558
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,0.001071048937317124,0.0011460282337114479
NCT01989585,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",0.001062518182295067,0.0011498356487433228
NCT01989572,Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma,0.0010905528303406904,0.0012469195006455343
NCT01989559,Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery,0.0010020218587211776,0.0011465522461051925
NCT01996202,A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma,0.0009009410313566966,0.0009071137697465432
NCT01990859,Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients,0.0013674231319198604,0.002125379619322487
NCT01959633,Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,0.001211975560422953,0.0012803606469020754
NCT01946373,T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma,0.00109092961393934,0.0010693976938497835
NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,0.0009288702506888459,0.0013371593157701478
NCT01944709,Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma,0.0012762224142887529,0.0012351364722447884
NCT01986712,A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma,0.0011251232806478815,0.001105529058140032
NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",0.0010955814589381223,0.0012524377056430517
NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,0.0007602919626324697,0.0010658370931331954
NCT01973608,MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma,0.0011858813009265569,0.0007508896647185325
NCT01961115,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,0.0011856329433320852,0.00143079200456491
NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,0.0014876290135930317,0.0011004386663299101
NCT01983124,Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib,0.0011851058776361995,0.0013521794754960007
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,0.0012605526387772293,0.0010161612288531806
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,0.0012174592896623951,0.0011455879177831722
NCT01904123,A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma,0.0012311039592162302,0.0011054615276834877
NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,0.0009262370810392611,0.0011779247264187326
NCT01988831,Efficacy of Propranolol Treatment to Prevent Melanoma Progression,0.0007933657063289618,0.0009427119787821358
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",0.0007366363814312212,0.0008557532826352649
NCT01984255,"A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",0.0010791572185266782,0.0009686158901993597
NCT02694965,Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma,0.0008596275251856153,0.0009049265091215854
NCT02602756,Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas,0.0010090200757674995,0.0008397308581531044
NCT02605473,Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion,0.0008410479120822648,0.0009478506574512235
NCT02659540,A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,0.0009349731960846428,0.0009457477916702213
NCT02696356,Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma,0.0012703250294573898,0.0011816053759982602
NCT02612168,Melanoma Image Analysis Algorithm (MIAA) Validation Study,0.0010084195486310052,0.0007796904019971077
NCT02671513,A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients,0.0013185037866658156,0.0017552600617720168
NCT02613325,fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth,0.0008337825301551,0.0009187402547831343
NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,0.0011447157121035646,0.0009912926922328962
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,0.0007400876850110499,0.0009754284413494532
NCT02600169,Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab,0.0010241592900953579,0.0011168554908128005
NCT02600143,Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.,0.0010043610629141672,0.000835673082974406
NCT02668887,Employment and Quality of Life in Patients With Malignant Melanoma,0.0015283714068834785,0.0010468469861794748
NCT02656706,BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,0.0009095601535730841,0.0008408562471509119
NCT02673970,Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma,0.0011066624213995435,0.0011607992425428295
NCT02662725,Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases,0.0011296331171821183,0.0009103739606509507
